GSK shares are trading higher after the company announced results from its DREAMM-9 phase III trial of Blenrep in combination with pomalidomide plus dexamethasone verses a standard of care as a second line and later treatment for relapsed or refractory multiple myeloma.
Portfolio Pulse from Benzinga Newsdesk
GSK shares are trading higher following the announcement of positive results from its DREAMM-9 phase III trial of Blenrep in combination with pomalidomide plus dexamethasone for treating relapsed or refractory multiple myeloma.
March 07, 2024 | 5:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's announcement of positive phase III trial results for Blenrep in treating multiple myeloma has led to an increase in its stock price.
The positive outcome of the DREAMM-9 phase III trial for Blenrep, a significant product in GSK's portfolio for treating multiple myeloma, directly impacts the company's stock price by increasing investor confidence in GSK's research and development capabilities and its potential for future revenue growth from this treatment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100